PharmaResearch (CEO Thinkyou Kim, Ki-seok Kang) celebrated the world’s first launch of CONJURAN® in Singapore.
The launch took place at St. Regis Singapore in August, featuring a symposium tailored for local orthopedists, anesthesiologists, and physiatrists. During the symposium, distinguished speakers, including Professor Moon-jong Chang of the SMG-SNU Boramae Medical Center and renowned doctors from Singapore, highlighted the exceptional qualities of CONJURAN® and PharmaResearch’s patented DOT®(DNA Optimizing Technology).
In particular, Professor Chang provided detailed insights into the effectiveness and stability of CONJURAN®, drawing from significant clinical results.
An official from PharmaResearch emphasized the significance of entering the Singaporean market, stating, “The launch of CONJURAN® in Singapore is a momentous step, marking PharmaResearch’s first entry into the global market. We hold high expectations for CONJURAN’s success in the osteoarthritis market, starting in Singapore, which serves as the hub of Asia.”
CONJURAN® is an advanced medical device that harnesses the power of polynucleotide (PN), a regenerative substance derived from salmon, by leveraging PharmaResearch’s patented DOT™. When injected into the glenoid cavity, it effectively reduces mechanical friction through physical restoration. CONJURAN® received approval from the Singapore Health Sciences Authority (HSA) in February.
Media Contact
Company Name: Pharmaresearch
Contact Person: Seulki Kwak
Email: Send Email
Country: South Korea
Website: http://pharmaresearch.co.kr/kor/